Transdel Pharmaceuticals, – developers of the revolutionary Transdel™ transdermal cream drug delivery platform and topical anti-inflammatory Ketotransdel® cream for acute pain, has been generating a buzz throughout the pharmaceutical industry producing rumors that TDLP may be on the verge of announcing some significant news.

Rumors that TDLP is close to landing deals within weeks with one or two major companies for an up-front $10M cash and FDA trial-expense deal are circulating rapidly, with online biomedical/financial news portal projecting the Company could receive 25% + in royalties.

CEO and CFO of TDLP, John Lomoro, a 15-year finance and accounting specialist in his own right, described the groundbreaking technology and the excellent market position in which this proprietary technology places TDLP as constituting considerable cause for excitement.

Lomoro noted how the Transdel technology, as in the case of Ketotransdel, is able to deliver the active drug Ketoprofen, a NSAID (non-steroidal anti-inflammatory drug), through the skin and directly to underlying tissues, thus avoiding first-pass metabolism in the liver and minimizing systemic exposure.

Essentially the proprietary technology employs a combination of penetrator enhancers to take the drug through the skin barrier and deliver it directly to targeted tissue systems. This technology represents a powerful platform for TDLP to develop other topical pharmaceutical/cosmetic products.

Lomoro explained that, since he came to work for the Company, he has fast-tracked the partnering-out of the Ketoprofen program, aggressively pursuing regional and global deals leading to current late-stage discussions with both a regional and global partner.

The Company seeks to broker a deal whereby a joint development committee would be established that allows the partner to participate in Phase 3 while acting as a funding mechanism for what is sure to be a massive revenue engine.

The cosmetic appeal of the cream, as opposed to its competitors, combined with the revolutionary Transdel technology, makes for easy-to-use products that present a very appealing uptake profile at the consumer level which is compatible with multiple drugs and allows for transdermal dosages to be developed for established drugs.

The size of the pain market is immense, but with recent safety/efficacy concerns about NSAIDs and Cox-2 inhibitors leading to Merck losing billions over Vioxx (and similar problems for Pfizer with Bextra and Celebrex), there is a big unsatisfied demand gap in the market.

Advent Transdel, an easy to use, comfortable and aesthetically attractive solution for patients, has an extremely good safety profile which doesn’t produce any of the side effects which would otherwise limit uptake in this market.